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Background: The discrepancy between the functional improvements yielded experimentally by skeletal myoblasts (SM) transplanted in
infarcted myocardium and the paucity of their long-term engraftment has raised the hypothesis of cell-mediated paracrine mechanisms.
Methods and results: We analyzed gene expression and growth factors released by undifferentiated human SM (CD56+), myotubes (SM
cultured until confluence) and fibroblasts-like cells (CD56−). Gene expression revealed up-regulation of pro-angiogenic (PGF), anti-
apoptotics (BAG-1, BCL-2), heart development (TNNT2, TNNC1) and extracellular matrix remodelling (MMP-2, MMP-7) genes in SM. In
line with the gene expression profile, the analysis of culture supernatants of SM by ELISA identified the release of growth factors involved in
angiogenesis (VEGF, PIGF, angiogenin, angiopoietin, HGF and PDGF-BB) as well as proteases involved in matrix remodelling (MMP2,
MMP9 and MMP10) and their inhibitors (TIMPs). Culture of smooth muscle cells (SMC), cardiomyocytes (HL-1) and human umbilical vein
endothelial cells (HUVECs) with SM-released conditioned media demonstrated an increased proliferation of HUVEC, SMC and
cardiomyocytes (pb0.05) and a decrease in apoptosis of cardiomyocytes (pb0.05). Analysis of nude rats transplanted with human SM
demonstrated expression of human-specific MMP-2, TNNI3, CNN3, PGF, TNNT2, PAX7, TGF-β, and IGF-1 1 month after transplant.
Conclusions: Our data support the paracrine hypothesis whereby myoblast-secreted factors may contribute to the beneficial effects of
myogenic cell transplantation in infarcted myocardium.
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Although cell therapy has emerged as an attractive new
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doi:10.1016/j.ejheart.2008.08.002currently investigated adult stem cell sources have convin-
cingly demonstrated a potential for significant long-term
engraftment and differentiation into functional cardiomyo-
cytes [6–8]. Nevertheless, in the specific case of skeletal
myoblasts (SM), the results of several preclinical and clinical
studies have shown improved functional outcomes following
transplantation of these myogenic progenitors into post-
infarction scars [9–11] (review in Ref. [12]). As thesed by Elsevier B.V. All rights reserved.
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still present in the engrafted areas, the hypothesis has been
raised that the improvement in cardiac function did not result
from an increase in the number of contractile cells intended
to replace those lost after damage, but from a paracrine
action from the transplanted cells. So far, however, the
pathways involved in the paracrine signalling triggered by
skeletal myoblasts have remained largely elusive. The
present study was therefore designed with three objectives
(1) to determine the differential gene expression profile of
SM and their progeny (myotubes) in comparison with
fibroblast-like cells; (2) to characterize the cytokines and
growth factors released by SM that could be implicated in the
effects observed after their transplantation in infarcted
myocardium, and (3) to correlate these in vitro findings
with those occurring in vivo. For this specific purpose, we
used tissue samples from a previous series (Ref. [13]) of rat
experiments in which human skeletal myoblasts had been
transplanted into infarcted areas.
2. Materials and methods
2.1. Cell populations
Human muscle biopsies, obtained after written informed
consent, from patients undergoing orthopaedic or cardiac
surgery were minced and digested with trypsin-EDTA
(0.5 mg/ml trypsin and 0.53 mM EDTA) and collagenase
(1.5 mg/ml) as previously described [2]. Cells were grown in
growth medium (GM) containing Ham-F12 media (GIBCO-
BRL), 20% foetal calf serum (FCS) and 1% penicillin/
streptomycin (GIBCO-BRL). By day 6 (50% confluence),
CD56+ cells were isolated using CD56 labelled microbeads
(Miltenyi Biotech, Germany) following the manufacturer's
instructions. Cells were plated and maintained for 15 days in
GM and three different populations of cells were obtained:
C56+ cells (SM), CD56− cells (fibroblast-like cells), and
myotubes (CD56+ cells allowed to fuse into myotubes by
high cellular confluence). Two million cells of each fraction
were harvested for RNA extraction. The study and all the
procedures were approved by the Institutional Review Board
for Human Studies and Ethics Committee and conform to the
principles outlined in the Declaration of Helsinki for use of
human tissue.
2.2. Oligonucleotide microarray analysis and validation
Total RNA from cells was isolated using the Trizol
reagent (Life Technologies, Gaithersburg, MD) and purified
with the Rneasy® Mini Kit (Qiagen, Valencia, CA)
following the manufacture's instructions. RNA levels,
quality and purity were assessed with the use of the RNA
6000 Nano assay on the Agilent 2100 bioanalyzer (Agilent,
Palo Alto, CA). None of the samples showed RNA
degradation or contamination with genomic DNA. After
reverse transcription, samples were hybridized in U133Amicroarray (Affymetrix). Array data were normalized with
MAS5.0 (Affymetrix Microarray Suite software). The
following parameters were examined to ensure that arrays
were well hybridized: all array Scale Factor (SF) were lower
than 2.5, the number of presences was higher than 25% in all
of the arrays and GAPDH values were ~1 and in any case
greater than 2.5. Data were filtered to eliminate probes
whose presence number is 0 and those whose intensity value
is less than 100 in 90% of the samples (7933 probes). Un-
supervised cluster analysis: hierarchical clustering based on
the average-linkage method with the centered correlation
metric was carried out using Cluster and Treeview software
[14]. Supervised analysis: in order to identify genes with
statistically significant changes in expression between
groups, we used two different algorithms to increase the
readability of the study: SAM (Significant Analysis of
Microarrays) [15] and GARBAN. GARBAN analysis was
based on genes where the differences between the 2 groups
using a t-test showed a p value b0.05 or 0.01. In the case of
SAM, all data were permuted over 100 cycles by using the
two class (unpaired) format. Classification of the genes
according to the Gene Ontology and matching of the gene
products in the Boehringer Mannheim chart of Biological
Pathways and the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) were made using the GARBAN software.
2.3. Quantitative-real-time PCR (Q-RT-PCR)
Total RNA was extracted from cells or frozen heart
sections using Trizol™ method (Invitrogen) following the
manufacturer's instructions. Human Universal Reference
Total RNA was purchased from BD Biosciences (USA) and
used as a positive control. Reverse transcription was
performed on 1 µg of total RNA, after heating at 70 °C for
5 min, with random hexamers as reaction primers. The
reaction was carried out at 42 °C for 45 min in the presence
of SuperScript™ reverse transcriptase (Invitrogen). Q-RT-
PCR was performed in a fluorescent thermal cycler (MJ
Research), using 1 µl of cDNA in 20 µl reaction volume with
300 nM of each primer, 250 nM of probe (SIGMA) and
Taqman™ (Roche). Primers used for PCR are shown in
Table 1. Amplification conditions were as follows: 95 °C for
3 min followed by 40 cycles consisting of 90 °C–60 s,
60 °C–60 s, 72 °C–60 s. All samples were also amplified to
detect the GAPDH gene as control.
2.4. Cytokine arrays
To obtain culture supernatants, cells were cultured for
48 h under hypoxic (5% O2) conditions in the absence of
serum to avoid the potentially confounding effect of serum-
derived growth factors on outcome measurements. After
48 h, the supernatants of SM cultures were collected and
frozen. Cytokine levels were measured by and ELISA
cytokine antibody array (Ray Biotech) according to the
manufacturer's instructions.
Table 1
Primers use for PCR analysis of human cells
Gene Forward Reverse Probe
Bcl-2 GAACCCCGGAAGAGGTAGCT TCCAGCCCAGGCACATG AGAAGGGAAGGCGCGAGTGAGGAAAG
CNN3 AGCTGGCCAAAGTGTAATTGGT TGGGATCATAAAGATGCCTCCTA CCAGGCAGGTATGACAGCTTACGGGA
MMP2 TCACTCCTGAGATCTGCAAACAG TCACAGTCCGCCAAATGAAC ACATTGTATTTGATGGCATCGCTCAGATCC
MMP7 TCCCCCTGCATTTCAGGAA TCCTGGCCCATCAAATGG ATCATGATTGGCTTTGCGCGAGGA
MMP9 CAGTCCACCCTTGTGCTCTTC GCCACCCGAGTTAACCATAG AGACCTGAGAACCAATCTCACCGACAGG
MYH7 TGAGACTGTCGTGGGCTTGTAT TGCTCAGCACCCTGTTTGCC TTGCCTTTGCCCTTCTCAAT
PAX7 GAGGACGACGGCGAAAAGA GTCAGGTTCCGACTCCACATC AACACAGCATCGACGGCATCCTGG
PGF GCGATGAGAATCTGCACTGTGT TCCCCAGAACGGATCTTTAGG AGACGGCCAATGTCACCATGCAGC
TNNC1 CAGCTGACAGAAGAGCAGAAAAAT TCACCTTGCCCAGCTCCTT AAGGCAGCCTTCGACATCTTCG
TNNI3 CCAACTACCGCGCTTATGC TCGAGGCGGAGATCTTAGATTT ACGGAGCCGCACGCCAAGA
TNNT2 GGCAGACTGAGCGGGAAAA CACAGCTCCTTGGCCTTCTC AAGATTCTGGCTGAGAGGAGGAAGGTGC
TGFB GCCGACTACTACGCCAAGGA AGAGCAACACGGGTTCAGGTA TCACCCGCGTGCTAATGGTGGA
IGF GGAAGTACATTTGAAGAACGCAAGT TGCGGTGGCATGTCACTCT AGTGCAGGAAACAAGAACTACAGGATGTAGGAAGA
SDF GCTGAAGAACAACAACAGACAAGTG TGACCCTCTCACATCTTGAACCT AGACCTGAGAACCAATCTCACCGACAGG
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Human SM were cultured under normoxic (21% 02) or
hypoxic (5% 02) conditions in F12 media supplemented with
2.5% FCS for the proliferation studies and with no serum for
the apoptosis studies and collected after 48 h. Alternatively,
F12 culture medium plus 2.5% serum was incubated without
cells, during the same period of time at 37 °C and 5% CO2 as
controls for the proliferation assays (non conditioned media
(NCM).
For proliferation studies, human umbilical cord blood
venous endothelial cells (HUVEC), smooth muscle cells
from cord blood or the rat derived cardiomyocyte cell line
HL-1 were cultured in six well plates (5000 cells/well) in the
presence of SM conditioned media (CM) (75% of the media)
or control media (NCM) with 5% FCS and after 72 h, the
number of viable cells was quantified by a nucleocounter
(Chemometec, Denmark) following manufacturer's proto-
col. Three independent experiments were performed and
every cell type grown in CM or NCM was seeded in
triplicate.
For apoptosis assays, HL-1 cells (250.000 cells) were
seeded in 96 well plates and cultured under hypoxic
conditions (1% O2) and no serum in the presence of CM
or NCM during 48 h. Apoptosis was measured using an
ELISA kit (Roche Applied Science, Spain) in which
oligonucleosomal fragments are quantified as we have
previously described [16]. Three independent experiments
were performed on cells seeded in triplicate.
2.6. In vivo transplantation study
Ligation of the left coronary artery was performed in
seven-week-old immunodeficient nude mu/mu rats (Harlan
France SARL, Gannat, France). Ten days later, rats under-
went a sternotomy and then were allocated to receive in-scar
injections (150 µl) of human SM (5×106, n=7), or culture
medium (n=4). The viability of cells after thawing, assessed
by fluorescence-activated cell sorting (FACS) using propi-dium iodide exclusion, was consistently N87%. All experi-
ments were performed in accordance with the “Principles of
Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources, Commission on Life Science,
National Research Council, and published by the National
Academy Press, revised 1996. Animals were sacrificed
30 days after injection of the SM. Explanted hearts were cut
into three segments and frozen in liquid nitrogen-cooled
isopentane. Heart tissue specimens were then assessed for
the expression of human-specific MMP-2, TNNI3, CNN3,
PIGF, TNNT2, PAX7, TGF-beta, and IGF-1 by real time
quantitative PCR (Q-RT-PCR). The functional results of this
group of animals have been previously reported [13].
2.7. Statistical analysis
All data are expressed as mean±SEM and comparisons
between two groups were analyzed by Mann Whitney U test.
Comparisons among 3 or more groups were analyzed by
Kruskall Wallis test. SPSS 12 software was used for
statistical analyses and differences were considered statisti-
cally significant when Pb0.05.
3. Results
3.1. Characterization of the gene expression profile of SM
The comparison between the gene expression profile of
undifferentiated populations of SM (CD56+ cells), fibroblast-
like cells (CD56− cells) and differentiated myotubes using the
Affymetrix high-density oligonucleotide arrays U133A
revealed that over 2093 were differentially expressed between
SM and fibroblasts (pb0.05) (Supplementary Online Table
S1). Following Gene Ontology classification, genes related to
regulation of transcription, cell cycle and development were
the most common genes differently expressed. The compar-
ison between myotubes and fibroblast-like cells revealed that
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mentary Online Table S2), the most common genes being
related to regulation of transcription and cell adhesion. The
comparison between SM and differentiated myotubes showed
909 differentially expressed genes (Supplementary Online
Table S3) predominantly related to regulation of transcription,
cell adhesion and G-protein signalling. As expected, dendro-
gram analysis clustered the samples in three different groups
according to the type of cells (data not shown).
As the goal of our study was to establish a link between
SM and the mechanisms of their beneficial effect following
in-scar transplantation, we first validated the expression of
genes differentially expressed between the different popula-
tions and implicated in pathways potentially involved in
cardiac repair (cardiac differentiation, angiogenesis, remo-
delling and apoptosis) by Q-RT-PCR (Fig. 1). Placental
Growth Factor (PlGF), a VEGF homologue that signals
through the VEGFR-1, was shown to be up-regulated in SM
in comparison with either differentiated cells or fibroblast-
like cells (Fig. 1). Genes implicated in heart development
(TNNT2-cardiac specific troponin T, TNNC1-cardiac spe-
cific Troponin I) and extracellular matrix remodelling
(metalloproteinases [MMPs] 2 and 7) were also found to
be up-regulated in SM or in myotubes in comparison with
fibroblast-like cells, whereas MMP-9 expression was only
found in differentiated cells. Skeletal myoblasts also
expressed transcription factors present in satellite cells
such as Pax7 and higher levels of the antiapoptotic geneFig. 1. Expression of genes implicated in cardiac repair. Q-RT-PCR for genes
extracellular matrix remodelling (MMP-2, MMP-7 and MMP-9), SM specific tran
SM, fibroblasts and differentiated myofibers. Expression levels are presented as pe
GAPDH as housekeeping gene. The mean (±SEM) of 4 different experiments inBcl-2 and of calponin, a protein involved in smooth muscle
contraction.
3.2. Characterization of cytokines and growth factors
released by SM
To establish a link between expression and release of
certain growth factors implicated in cardiac repair, we
analyzed the profile of cytokines secreted by SM by an
ELISA array. In line with the gene expression profile
analysis, a number of growth factors implicated in
angiogenesis were released by SM including VEGF, PlGF,
angiogenin, angiopoietin, HGF and PDGF-BB (Table 2).
Interestingly, proteases involved in matrix remodelling
(MMPs) and their inhibitors (TIMPs) were also detected in
the supernatants of SM cultures albeit at variable levels
(Table 2).
To determine the functional effect of these cytokines on
cell proliferation and apoptosis we examined the cellular
effects of SM-derived conditioned media obtained under
both normoxic (21% O2) and hypoxic (5% O2) conditions to
more closely match the milieu in which the SM are
transplanted (scar tissue with low oxygen supply). Prolifera-
tion of HUVECs was found to be increased in the presence of
conditioned media obtained both under normoxia (3.1±0.9
fold increase pb0.05) and hypoxia (5.0±2.0 fold increase;
pb0.05) in comparison with standard media. Similarly,
conditioned media induced an increase in smooth muscle cellinvolved in angiogenesis (PIGF), heart development (TNNT2, TNNC1),
scription factors (Pax7), apoptosis (Bcl-2) and smooth muscle (calponin) on
rcentages in comparison with SM expression and were normalized by using
triplicate is shown. ⁎ (pb0.05).
Table 2
Secretion of growth factors and cytokines by SM under hypoxic conditions
pg/ml SM
Angiogenin 404.6±78.5
Angiopoietin-2 12.5±8.8
EGF 0.03±0.02
bFGF 1.18±0.87
HB-EGF 1.4±1.0
HGF 241±135
Leptin 1.01±0.65
PDGF-BB 0.38±0.34
PlGF 195.0±90.3
TGFb 501.7±21.8
VEGF 774.2±33.6
MMP-1 2930±2200
MMP-2 340±245
MMP-3 4170±2070
MMP-8 0.9±0.0
MMP-9 4.4±0.0
MMP-10 24690±11980
MMP-13 29±28
TIMP-4 10±0
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and normoxia respectively; pb0.05) and HL-1 proliferation
(1.7±0.3 pb0.05 and 1.4±0.2 fold increase, in hypoxia and
normoxia respectively) (Fig. 2). Although there was a trend
to higher cytokine secretion in hypoxic conditions, these
differences did not reach statistical significance. In addition,
culture of cardiomyocytes with myoblast-derived condi-
tioned media prevented apoptosis of HL-1 cells (40±3%
reduction; pb0.05) in comparison with control media
(Fig. 3).
3.3. In vivo findings
To examine whether cytokines found by ELISA could
also be detected in an in vivo model, we analyzed sections of
rat hearts subjected to a chronic myocardial infarction and
transplanted with human derived SM. As previously
described [13], these hearts had demonstrated a better
functional recovery than medium-injected control hearts, as
evidenced by higher ejection fractions, smaller increases in
endsystolic volumes and a leftward shift in preload-
recruitable stroke work. Three samples of each heart were
obtained from the infarcted zone where the myoblasts had
previously been immunohistochemically detected. Twenty-
five serial cryostat sections of 25 µm thickness were
obtained from each sample for human RNA detection. In 6
out of 7 SM-transplanted animals, Q-RT-PCR detected a
positive signal for MMP-2, TNNI3, CNN3, PIGF, TNNT2,
TGF-β and IGF-1 that ranged between 0.02% and 88% in
comparison with a universal human mRNA control
(Table 3). In contrast, expression of human-specific mRNA
was not detected in animals injected with control media
suggesting that these growth factors are released in vivo after
transplantation of SM, can be detected up to 1 month aftertransplant and thus might have contributed to the functional
effects associated with SM treatment of MI.
4. Discussion
It is now commonly accepted that regardless of their
origin, transplanted cells do not survive well in the host
myocardium, with studies reporting 70% to 93% of cell
death in only the first 3 days and with an increased cell death
over time [17–20]. Despite this, most preclinical studies
have reported that cell transplantation improves the func-
tional outcome in both ischaemic and nonischaemic
cardiomyopathy models [1,10,21]. To account for this
discrepancy, it has been hypothesised that the benefit of
the procedure is not related to the addition of new donor-
derived contractile elements but rather to indirect effects like
mechanical limitation of remodelling (“girdling” effect) or
paracrine actions of the graft on the host tissue. So far, this
paracrine paradigm has been primarily investigated in bone
marrow cells and analysis of the secretome of these cells
tends to confirm that the pathways that they activate involve
increased angiogenesis, limitation of apoptosis, changes in
extracellular matrix composition effecting greater scar
elasticity and, more hypothetically, recruitment of endogen-
ous cardiac stem cells [22–25]. In contrast, the putative
paracrine effects of SM have been less well deciphered [26].
Nevertheless, with the exception of the recently described
skeletal precursors of cardiomyocyte cells (Spoc) isolated
from mouse muscle, which have demonstrated their potential
to differentiate into beating and functional cardiomyocytes
both in vitro an in vivo [27], the general consensus is that SM
do not differentiate into cardiomyocytes [6]. Therefore, the
paracrine hypothesis looks like a sound mechanism to
explain the experimentally-demonstrated improvement of
function in myoblast-grafted failing hearts independently of
true cardiac regeneration [9,26,28–32]. Overall, our micro-
array data, more directly validated by Q-RT-PCR measure-
ments, suggests that injected SM, differentiated myotubes
expected to result from their in vivo fusion and fibroblast-
like cells that contaminate myoblast injections, release
important factors involved in angiogenesis, remodelling
and apoptosis inhibition pathways that can ultimately lead to
enhanced cardiac tissue protection.
Thus, the profile of genes expressed by SM in comparison
with the other two sources of cells supports the potential of
SM to produce proteins that can induce angiogenesis and
vasculogenesis. An increase in PIGF may amplify the
responsiveness of endothelial cells to VEGF and thus
contribute to increase angiogenesis in the ischaemic
myocardium [33] as we have demonstrated in a swine
model of chronic myocardial infarction treated with auto-
logous SM [9] while up-regulation of calponins (CNN3), a
family of proteins involved in smooth muscle contraction,
supports the potential of transplanted cells to differentiate
into smooth muscle, as we have previously reported [9]. A
relation between VEGF, angiogenesis, and cardiac repair
Fig. 3. Effect of conditioned media on apoptosis of HL-1 cardiomyocytes.
Cardiomyocytes (HL-1) were cultured for 48 h in either standard media
(control) or conditioned media from SkM obtained under hypoxic or
normoxic conditions after which apoptosis was measured as described in the
Materials and methods. The mean±SEM of 3 different experiments in
triplicate is shown. ⁎ (pb0.05).
Fig. 2. Effect of conditioned media on proliferation of HUVEC, smooth muscle cells and cardiomyocytes. Endothelial cells (HUVEC) (A), smooth muscle cells
(B) and cardiomyocytes (HL-1) were cultured for 48 h in either standard media (control) or conditioned media from SkM obtained under hypoxic or normoxic
conditions and the number of cells analyzed. Cell proliferation in conditioned media is represented as a percentage in comparison with standard media (100%).
Microphotographs in A, B and C show a representative experiment of 3 different studies while graphs represent the mean±SEM of 3 different experiments in
triplicate. ⁎ (pb0.05).
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has been recently demonstrated in a murine model of MI
[34].
Cell transplantation has also been associated with
prevention of cardiomyocyte apoptosis [35]. The up-
regulation of antiapoptotic genes like BAG-1 and Bcl-2,
previously linked to enhanced cell survival in ischaemia-
reperfusion models [36,37] as well as the ability of SM-
derived supernatants to decrease HL-1 cardiomyocyte
apoptosis in vitro indicate that SM could also contribute to
mitigate post-infarction cell death. Although SM are not
endowed with the potential to differentiate into cardiomyo-
cytes, [6] expression of cardiac specific genes was surpris-
ingly detected in SM and differentiated cells such as troponin
I (TNNC1) [38], cardiac specific troponin T (TNNT2) [39],
cardiac troponin I (TNNI3) and β-myosin heavy chain
(MYH7) albeit at low levels (0.3–1% of cardiomyocytes in
comparison with cardiomyocytes). These findings suggest
that SM could contain a genetic program that, under specific
circumstances, would allow them to partially differentiate
into cardiac muscle or at least that a population of cells
within the myoblast pool could have this potential [27].Cardiac remodelling ensues after myocardial infarction
and contributes to the development of fibrosis and eventually
heart failure [40]. While changes in the balance between
MMPs and their natural inhibitors (TIMPs) participate in the
derangement of the heart after infarction [41], transplantation
Table 3
Expression of cytokines in rat hearts as a percentage in comparison with
universal human mRNA
SM (mean±SEM)
TNNT2 33.4±14.9%
TNNI3 55.0±23.1%
PlGF 1.6±0.8%
CNN3 1.7±0.9%
IGF-1 0.3±0.1%
TGF-β 0.03±0.01%
MMP-2 0.9±0.5%
PAX7 29.0±12.0%
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changes in the matrix remodelling process [9]. In our study,
matrix MMPs such as MMP-7 (involved in the early stage of
tissue remodelling [42]) and the gelatinase MMP-2 were up-
regulated in SM. MMP2 may be an important player in
regulating SMC phenotype, proliferation, migration and in
maintaining the integrity of the vascular wall through
governing proteolysis during arteriogenesis [43]. Moreover,
activated MMP-2 could bind to αvβ3 on the surface of
angiogenic endothelial cells, and may influence angiogenesis
by inducing vascular migration [44].
The results of the ELISA on SM culture supernatant
establish a link between gene expression and secretion of
growth factors by SM, which is further supported by the
functional effect of the culture supernatants on proliferation
and apoptosis of smooth muscle, endothelial and cardiac
cells. The ultimate link between the paracrine effects of SM
demonstrated in vitro and the functional benefits associated
with their intramyocardial injection was best provided by the
results of our xeno-myoblast transplantation study showing
that the engrafted cells acted as cytokine sinks releasing
some of the factors involved in the key events (particularly,
increased angiogenesis and decreased fibrosis) that con-
tribute to tissue salvage. Of note, these cytokines could be
detected for as long as 1 month after cell transplantation in
spite of the low percentage of SM that was still engrafted at
this remote time point. Of note, the functional results of this
group of animals, which have been reported previously [13],
showed a preservation of left ventricular function, compared
with controls; this finding is consistent with the paracrine
paradigm in that, in a rabbit model of occlusion/reperfusion
subjected to bone marrow cell transplantation, levels of
TGF-β and MMP-1 were negatively correlated with post-
treatment ejection fractions [24].
Put together, these data might, at least partly, explain the
findings of the randomised controlled MAGIC trial in which
left ventricular enddiastolic and endsystolic volumes of
patients injected with a high dose of SM were significantly
reduced compared with those receiving a low dose of cells or
the placebo medium [45]. At the end, the trophic effects of
SM were best evidenced by the ability of SM-derived
conditioned media to enhance the proliferation of the major
cell types that constitute myocardial tissue, particularlyunder hypoxic conditions simulating the scarred environ-
ment in which cells are usually transplanted.
In conclusion, our study provides new insights into some of
the mechanisms that participate in the putative benefit of SM-
induced cardiac repair. However, apart from this cognitive
information, the present results may also have more practical
implications. Namely, if a predominant mode of action of SM
is the release of cardioprotective factors, then one could
consider delivering these cells encapsulated in microparticles
that allow an inward flux of oxygen and nutrients ensuring
graft viability and an outward flux of cell-released products
while the size of the external membrane pores is sized in a way
that prevents invasion by immune cells. Such a delivery
system should limit the inflammatory component of cell death
while allowing transplantation of allogeneic cells, thereby
circumventing some of the hurdles associated with autologous
cell therapy products (variable functionality, delayed avail-
ability, cost of customized quality controls). The successful
control of diabetes by transplantation of encapsulated insulin-
producing allogeneic and even xenogeneic cells suggests that
this option is clinically realistic [46].
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